In a move that underscores the growing influence of private equity in healthcare, Avanos Medical is set to go private in a deal valued at approximately $1.27 billion, marking a dramatic shift for the publicly traded medical device firm.

The acquisition, led by American Industrial Partners, highlights a broader trend reshaping the healthcare industry—one where private capital is increasingly stepping in to drive transformation, efficiency, and long-term growth.

For Avanos, the decision to go private represents a major turning point.

Public companies operate under constant scrutiny from investors, analysts, and regulators—pressures that can limit long-term strategic planning.

By transitioning to private ownership, Avanos will gain the flexibility to focus on innovation, restructuring, and growth without the burden of quarterly earnings expectations.

This is particularly important in the medical technology sector, where research and development cycles can be lengthy and capital-intensive.

American Industrial Partners is no stranger to large-scale acquisitions, but this deal signals strong confidence in Avanos’s future potential.

The company specializes in products that address critical healthcare needs, including pain management and recovery solutions—areas with growing demand as healthcare systems worldwide evolve.

Private equity firms typically invest with a long-term horizon, aiming to enhance operational efficiency, expand market reach, and eventually realize significant returns.

In Avanos’s case, that could involve:

News of the deal has sparked significant interest among investors.

Shares of Avanos surged as the acquisition price reflected a premium over its market value—a common feature of buyout deals.

For shareholders, this represents an immediate financial gain.

For the company, it marks the beginning of a new chapter.

This acquisition is part of a larger movement.

Private equity firms have been increasingly active in the healthcare sector, attracted by its resilience, growth potential, and critical role in society.

From hospitals to biotech startups, private capital is reshaping how healthcare businesses operate.

Critics, however, warn that this trend could prioritize profits over patient outcomes.

Supporters argue that private equity brings much-needed investment and efficiency to an industry often burdened by bureaucracy.

The company has already been undergoing significant changes in recent years, including divestitures and strategic realignments aimed at focusing on core growth areas.

Going private could accelerate this transformation.

Freed from public market pressures, Avanos may be better positioned to execute bold strategies and take calculated risks.

While financial headlines often focus on valuations and deals, the real impact lies in patient care.

If the acquisition leads to improved products, faster innovation, and better outcomes, it could benefit millions of patients worldwide.

However, the outcome will depend on how effectively the new owners balance profitability with healthcare priorities.

The deal is expected to close pending regulatory approvals and customary conditions.

Once completed, Avanos will join a growing list of healthcare companies transitioning to private ownership.

For American Industrial Partners, the challenge will be delivering on its investment thesis.

For Avanos, the opportunity is clear: reinvent itself for a new era.

And for the healthcare industry, this deal is yet another sign that change is not just coming—it’s already here.